TY - JOUR
T1 - Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry
AU - Cikes, Maja
AU - Jakus, Nina
AU - Claggett, Brian
AU - Brugts, Jasper J
AU - Timmermans, Philippe
AU - Pouleur, Anne-Catherine
AU - Rubis, Pawel
AU - Van Craenenbroeck, Emeline M
AU - Gaizauskas, Edvinas
AU - Grundmann, Sebastian
AU - Paolillo, Stefania
AU - Barge-Caballero, Eduardo
AU - D'AMARIO, DOMENICO
AU - Gkouziouta, Aggeliki
AU - Planinc, Ivo
AU - Veenis, Jesse F
AU - Jacquet, Luc-Marie
AU - Houard, Laura
AU - Holcman, Katarzyna
AU - Gigase, Arno
AU - Rega, Filip
AU - Rucinskas, Kestutis
AU - Adamopoulos, Stamatios
AU - Agostoni, Piergiuseppe
AU - Biocina, Bojan
AU - Gasparovic, Hrvoje
AU - Lund, Lars H
AU - Flammer, Andreas J
AU - Metra, Marco
AU - Milicic, Davor
AU - Ruschitzka, Frank
PY - 2019
Y1 - 2019
N2 - Aims To compare characteristics of left ventricular assist device (LVAD) recipients receiving a cardiac implantable electronic device (CIED) with a defibrillator component (implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillation, CIED-D) vs. those without one, and to assess whether carrying such a device contiguously with an LVAD is associated with outcomes.Methods and results Overall, 448 patients were analysed (mean age 52 +/- 13 years, 82% male) in the multicentre European PCHF-VAD registry. To account for all active CIED-Ds during ongoing LVAD treatment, outcome analyses were performed by a time-varying analysis with active CIED-D status post-LVAD as the time-varying covariate. At the time of LVAD implantation, 235 patients (52%) had an active CIED-D. Median time on LVAD support was 1.1 years (interquartile range 0.5-2.0 years). A reduction of 36% in the risk of all-cause mortality was observed in patients with an active CIED-D [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.46-0.91; P = 0.012), increasing to 41% after adjustment for baseline covariates (HR 0.59, 95% CI 0.40-0.87; P = 0.008) and 39% after propensity score adjustment (HR 0.61, 95% CI 0.39-0.94; P = 0.027). Other than CIED-D, age, LVAD implant as redo surgery, number of ventricular arrhythmia episodes and use of vasopressors pre-LVAD were remaining significant risk factors of all-cause mortality. Incident ventricular arrhythmias post-LVAD portended a 2.4-fold and 2.6-fold increased risk of all-cause and cardiovascular death, respectively; carrying an active CIED-D remained associated with a 47% and 43% reduction in these events, respectively.Conclusions In an analysis accounting for all active CIED-Ds, including those implanted during LVAD support, carrying such a device was associated with significantly better survival during LVAD support.
AB - Aims To compare characteristics of left ventricular assist device (LVAD) recipients receiving a cardiac implantable electronic device (CIED) with a defibrillator component (implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillation, CIED-D) vs. those without one, and to assess whether carrying such a device contiguously with an LVAD is associated with outcomes.Methods and results Overall, 448 patients were analysed (mean age 52 +/- 13 years, 82% male) in the multicentre European PCHF-VAD registry. To account for all active CIED-Ds during ongoing LVAD treatment, outcome analyses were performed by a time-varying analysis with active CIED-D status post-LVAD as the time-varying covariate. At the time of LVAD implantation, 235 patients (52%) had an active CIED-D. Median time on LVAD support was 1.1 years (interquartile range 0.5-2.0 years). A reduction of 36% in the risk of all-cause mortality was observed in patients with an active CIED-D [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.46-0.91; P = 0.012), increasing to 41% after adjustment for baseline covariates (HR 0.59, 95% CI 0.40-0.87; P = 0.008) and 39% after propensity score adjustment (HR 0.61, 95% CI 0.39-0.94; P = 0.027). Other than CIED-D, age, LVAD implant as redo surgery, number of ventricular arrhythmia episodes and use of vasopressors pre-LVAD were remaining significant risk factors of all-cause mortality. Incident ventricular arrhythmias post-LVAD portended a 2.4-fold and 2.6-fold increased risk of all-cause and cardiovascular death, respectively; carrying an active CIED-D remained associated with a 47% and 43% reduction in these events, respectively.Conclusions In an analysis accounting for all active CIED-Ds, including those implanted during LVAD support, carrying such a device was associated with significantly better survival during LVAD support.
KW - Advanced heart failure
KW - Cardiac implantable electronic device
KW - Cardiac resynchronization therapy
KW - Implantable cardioverter-defibrillators
KW - Left ventricular assist devices
KW - Mortality
KW - Ventricular arrhythmia
KW - Advanced heart failure
KW - Cardiac implantable electronic device
KW - Cardiac resynchronization therapy
KW - Implantable cardioverter-defibrillators
KW - Left ventricular assist devices
KW - Mortality
KW - Ventricular arrhythmia
UR - https://iris.uniupo.it/handle/11579/175802
U2 - 10.1002/ejhf.1568
DO - 10.1002/ejhf.1568
M3 - Article
SN - 1388-9842
VL - 21
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 9
ER -